Abstract 455P
Background
Around 5 -10% of GIST lack driver mutations (KIT, PDGFR alpha) and are deficient in succinate dehydrogenase. Succinate Dehydrogenase deficient GISTs are unique in the fact that they occur predominantly in the younger population, are multifocal and generally resistant to imatinib. Surgery is a mainstay, but recurrence is common. Data regarding SDH deficient GIST from Indian subcontinent is very sparse.
Methods
This is a retrospective study of patients with SDH deficient GIST who presented to the sarcoma GIST/clinic in All India Institute of Medical Sciences, New Delhi, India from 2016-2022. 9 out of 120 GIST patients (7.5%) were SDH deficient. All patients were discussed in sarcoma/GIST tumor board and pathologies were re-reviewed by dedicated sarcoma/GIST pathologist. Data was collected retrospectively from prospectively maintained database.
Results
There were 9 patients with median age of 48 years (range 15-63), of which there were 5 males (n=5, 55.5%). 8 patients (n=8, 88.8%) had primary in stomach, 1 had duodenal GIST. In stomach, body was the most common location (n=6,75%). 3 out of 9 patients (n=3, 33.3%) had multifocal disease. 8 out of 9 (88.8%) had metastasis at presentation. Most common site of metastasis was liver (7 out of 8, 87.5%) Lymph node involvement was present in 4 out of 9 patients (44.4%). One patient had classical Carneys triad at presentation. 8 out of 9 (88.8%) had epithelioid morphology and 1 (11.1%) had mixed epithelioid-spindle picture. 5 out of 9(55.5%) patients had germline SDH mutations. Out of 9 patients, 1 was put on observation post surgery and therapy was given for 8 patients(n=8,88.8%). None of the 8 patients responded to imatinib, 3 out of 5 patients (60%) had response with sunitinib, 3 were started on regorafenib out of which 1 had partial response and 1 patient had partial response with temozolamide. Median overall survival was NR- not reached (95% CI 12.96-NR).
Conclusions
Majority of patients with SDH deficient GIST had advanced disease and most of them were in stomach and had epithelioid morphology. We had male preponderance as compared to literature and higher age. Also there was poor response to first line tyrosine kinase inhibitors like imatinib. Based upon this data we have incorporated SDH IHC upfront in all cases similar to CAP guidelines.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
462P - Limited duration of treatment with checkpoint inhibitors in complete responders, yet prolonged survival: A real-world study from India
Presenter: Nitin Murthy
Session: Poster viewing 06
463P - Cost effectiveness of palbociclib and ribociclib in metastatic breast cancer in India using ICER and QALY
Presenter: Krishnamani Kalpathi
Session: Poster viewing 06
464TiP - Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design
Presenter: Alexander van Akkooi
Session: Poster viewing 06
465TiP - Evaluation of quality of life and functional outcomes following limb salvage surgery in extremities sarcomas
Presenter: naveen kushwaha
Session: Poster viewing 06
YO2 - A case of locally advanced breast cancer with biomarker conversion successfully treated with neoadjuvant chemotherapy-immunotherapy combination
Presenter: Long Nguyen
Session: Poster viewing 06
YO3 - Metastatic Breast cancer to esophagus: A case report and review of literature
Presenter: Bhuvana J
Session: Poster viewing 06
YO4 - Succinate Dehydrogenase deficient GISTs is a diagnostic and therapeutic dilemma? : A case report.
Presenter: Nurazzahra Kamarudin
Session: Poster viewing 06
YO5 - Complete Radiologic and Pathologic Response in a Metastatic Gallbladder Adenocarcinoma Patient treated with Checkpoint Inhibitor/Chemotherapy Combination: A Case Report
Presenter: Tisha Gay Tancongco
Session: Poster viewing 06
YO7 - Orbital Metastasis in Prostrate Cancer: A Case Report
Presenter: Shabnam Rehman
Session: Poster viewing 06
YO10 - BRCA2 Mutated Recurrent Adult Granulosa Cell Tumor Treated with PARP Inhibitor
Presenter: Debapriya Mondal
Session: Poster viewing 06